ArticleJournal of the West African College of Surgeons
To Evaluate and Compare the Effectiveness of Topical Amlexanox, Curcuma Longa Extract, and Clobetasol Propionate in the Treatment of Oral Lichen Planus: An Original Research.
Article in Journal of the West African College of Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lichen planus is a chronic autoimmune inflammatory mucocutaneous disease affecting the skin and oral mucosa. Objectives: The objectives of the study were to evaluate and compare the effectiveness of topical Amlexanox, Curcuma longa extract, and clobetasol propionate in the treatment of oral lichen planus (OLP). Materials and Methods: A total of 45 patients with OLP were randomly divided into three groups: Group I (Amlexanox), Group II (Curcuma longa extract), and Group III (Clobetasol propionate). Baseline recordings of pain and burning sensation were conducted using the visual analog scale (VAS) and numeric rating scale (NRS). Clinical signs of erythema, ulceration, and lesion size were evaluated and recorded. All patients were evaluated at weekly intervals during the 2-month therapy period, as well as during follow-up for 3 months (at 15-day intervals). Results: Amlexanox showed a significant reduction in pain and burning sensation, along with a decrease in clinical signs of OLP. However, complete remission was not achieved, and mild reappearance of erythema was observed. Curcuma longa extract also showed a significant reduction in pain and burning sensation, with a considerable reduction in clinical signs to a tolerable level. This reduction remained static during the follow-up period. Clobetasol propionate demonstrated higher efficacy in reducing pain, burning sensation, and clinical signs of OLP. Although complete remission was achieved during the therapy period, the reappearance of pain, burning sensation, and clinical signs was noted during follow-up visits. Conclusion: Amlexanox and Curcuma longa extract reduce the signs and symptoms of OLP to a tolerable level, with improvement remaining static after the cessation of therapy. Clobetasol propionate causes complete remission of signs and symptoms of OLP, but there is a higher chance of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.